Biotech Firm Artiva Ceases Operations After Two Deaths in Cell Therapy Trial

San Diego-based Artiva Biotherapeutics is winding down operations after two participants died during a Phase II cell therapy study for autoimmune diseases. One death was linked to chemotherapy complications preceding cell infusion, while the second, occurring two months post-treatment, remains undetermined but not directly attributed to the treatment by investigators. This incident highlights ongoing safety concerns in cell therapy development.